*Read Disclaimer Sponsored Content
{{current_date_full}} | Unsubscribe
Hello!
New Alert: 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP)
SXTP is our new NASDAQ high-growth alert.
SXTP is a NASDAQ listed pharmaceutical company that, unlike most early-stage biotechs, already has an FDA-approved drug generating commercial revenue.
The company is now working to unlock what could be a far larger opportunity with that same drug - for a serious tick-borne illness that has no FDA-approved treatment.
SXTP “specializes in developing and marketing new medicines for the treatment and prevention of infectious diseases that affect the lives of millions of people”.
SXTP “achieved FDA approval of its lead product, ARAKODA® (tafenoquine), for malaria prevention in 2018”.
Malaria, which is caused by the bite of the Anopheles mosquito, is one of the most serious, life-threatening infectious diseases in the world.
Globally in 2022, an estimated 249 million malaria cases and 608,000 malaria deaths were reported in 85 tropical countries.
“ARAKODA is the only FDA-approved, broad spectrum, once-weekly prescription malaria prevention on the U.S. market.”
“ARAKODA is a treatment of choice by travelers departing to regions of the world where malaria is endemic.”
“According to the Centers for Disease Control and Prevention, the long terminal half-life of tafenoquine, which is approximately 16 days, may offer potential advantages in less-frequent dosing for prophylaxis for malaria.”
Tafenoquine was approved for malaria prophylaxis in 2018 in the United States as ARAKODA® and in Australia as KODATEF®.
Both were commercially launched in 2019 and are currently distributed through pharmaceutical wholesaler networks in each respective country.
They are available at retail pharmacies as a prescription-only malaria prevention drug.
Now, using ARAKODA (tafenoquine), SXTP is looking to solve another problem:
Babesiosis is one of the most serious tick-borne diseases in America - and most people have never heard of it.
The disease is “a serious and debilitating emerging tick-borne illness often found as a co-infection in patients with Lyme disease. Symptoms include fevers, chills, sweats, and fatigue. Babesiosis can be life-threatening in elderly and immunosuppressed patients, relapsing multiple times. Incidence of the disease is rising.”
The most vulnerable patients face a particularly grim reality: once babesiosis begins relapsing in immunosuppressed patients - those undergoing chemotherapy, transplant recipients, or those with autoimmune conditions - conventional treatments frequently fail them entirely.
And yet: “No FDA-approved treatment or vaccine exists for babesiosis.”
“Insurance claims research commissioned by the Company suggest that the minimum annual incidence of babesiosis is at least 25,000 cases per year, although the true number may be much larger than this.”
As the company stated in November:
“After completing a 6,000 patient nationwide survey and quantitative research study, we announced on July 15, 2025 that we had determined the total addressable market (TAM) for Babesiosis treatment to be up to $1.1 billion through patent expiration in 2035.”
In March 2026, SXTP announced what could be the most important data in its history:
“60 Degrees Pharmaceuticals Announces All Patients Cured of Babesiosis After Tafenoquine Treatment in Expanded Use Clinical Trial”
“All three patients enrolled in study have been cured, confirming high cure rate of tafenoquine in immunosuppressed patients, as reported by Yale in a 2024 publication”
The study evaluated the ARAKODA regimen "combined with atovaquone and other antimalarials/antibiotics administered to patients with risk factors for severe disease with relapsing babesiosis who have previously failed conventional antimicrobial regimens.”
When combined with a prior 2024 Yale study, the data become remarkable:
“Collectively, in the seven patients evaluated (the Yale study and the Company’s study, combined), the data suggest that the cure rate for relapsing babesiosis in immunosuppressed patients approaches 100 percent when weekly tafenoquine is added to a patient’s background atovaquone-containing combination regimen and sustained until two negative PCRs are noted.”
Crucially, cure was confirmed using two highly sensitive independent tests - including "a U.S. Food and Drug Administration (FDA)-approved RNA amplification test used for blood donation screening that is at least 1,000 times more sensitive than standard commercial RT-PCRs”.
“Given the rarity of relapsing immunosuppressed patients and the high cure rate associated with adding tafenoquine, the Company believes it is an appropriate time for widely accepted treatment guidelines to be reviewed in light of the new data.”
Australian Chestnut Extract: A Near-Term Non-Prescription Catalyst
Beyond tafenoquine, SXTP is developing an entirely separate consumer market product.
In January 2026, the company announced:
“60 Degrees Pharmaceuticals Exercises License Option with Florida State University for Large-Scale Purification of Castanospermine for Non-Rx Use”
Company ready to commence regulatory process to secure access to U.S. market for Australian Chestnut Extract as a botanical product for non-prescription uses
“According to recent scientific literature, at low doses, castanospermine modulates carbohydrate metabolism, altering glycogen, glucose levels, and other clinical markers. In animal models, high doses have been shown to impact disease outcomes in several therapeutic areas, through immunomodulation.”
In March 2026, the company announced:
“60 Degrees Pharmaceuticals Files New Dietary Ingredient Notification (NDIN) with FDA for Australian Chestnut Extract”
“FDA has until May 25, 2026 to object to the notification, after which the Company will be free to market its proposed dietary supplement containing Australian Chestnut Extract”
“Company has signed an option agreement with Florida State University (FSU) to license a capsule formulation, expanding on its recent exercise of a license option for large-scale production”
On the commercial side, SXTP is building the sales infrastructure and distribution partnerships.
SXTP “collaborates with prominent research organizations in the U.S., Australia, and Singapore”.
Furthermore, the company’s “mission has been supported through in-kind funding from the U.S. Department of Defense and private institutional investors”.
In January 2026, the company announced:
“60 Degrees Pharmaceuticals Announces Partnership with Runway Health to Provide International Travelers Direct Access to ARAKODA® for Malaria Prevention”
“Partnership adds a travel-focused consumer telehealth platform to the ARAKODA® marketing strategy, offering a new convenience to people planning travel to malaria-endemic regions of the world”
It adds a new platform to the 60 Degrees Pharma ARAKODA marketing strategy, where eligible users can match their travel itinerary with a personalized medical treatment plan designed by a U.S. licensed healthcare provider.
In February 2026, the company announced:
“60 Degrees Pharmaceuticals Expands Access to ARAKODA® with GoodRx Partnership”
“GoodRx to offer prescription savings of up to 30% for ARAKODA® (tafenoquine)”
“Collaboration designed to lower patient out-of-pocket costs and expand the reach of Company’s marketing strategy”
“Partnership will improve the affordability of ARAKODA at over 70,000 pharmacies nationwide for people planning travel to malaria-endemic regions”
In March 2026, the company announced:
“60 Degrees Pharmaceuticals Announces 2025 Annual Results”
“FY 2025 net product revenues increased 65% to $1,005,000”.
In addition, this morning the company released breaking news:
“60 Degrees Pharma Announces ARAKODA (tafenoquine) for Malaria Prevention is Now Available on Runway Health Travel Website”
“Travelers can now purchase the only once-weekly, broad-spectrum malaria preventive online, through the Runway Health telehealth platform”
We believe SXTP could be positioned for high growth.
Make sure to do your own due diligence.
Happy Trading!
SmallCapStocks Team
Note: We encourage all traders and investors to develop personal trading rules that you can follow and that work for you. Always protect your downside and note that we alert extremely volatile short-term opportunities. Before investing in securities, you should always consult with your financial, tax and legal advisor and never invest money you cannot afford to lose.
DISCLAIMER:
You should read and understand this disclaimer in its entirety before joining the website or email/blog list of SmallCapStocks.com (the “Publisher”). The information (collectively the “Advertisement”) disseminated by email, text or other method by the Publisher including this publication is a paid commercial advertisement and should not be relied upon for making an investment decision or any other purpose. The Publisher is engaged in the business of marketing and advertising the securities of publicly traded companies in exchange for compensation. The track record, gains, upside, and/or losses mentioned in the Advertisement, if any, should not be considered as true or accurate or be the basis for an investment. The Publisher does not verify the accuracy or completeness of any information included in the Advertisement. While the Publisher does not charge for the SMS service, standard carrier message and data rates may apply. To unsubscribe from receiving promotional text messages to your phone sent via an autodialer, using your phone reply to the sender’s phone number with the word STOP or HELP for help.
The Advertisement is not a solicitation or recommendation to buy securities of the advertised company. An offer to buy or sell securities can be made only by a disclosure document that complies with applicable securities laws and only in the states or other jurisdictions in which the security is eligible for sale. The Advertisement is not a disclosure document. The Advertisement is only a favorable snapshot of unverified information about the advertised company. An investor considering purchasing the securities, should always do so only with the assistance of his legal, tax and investment advisors. Investors should review with his or her investment advisor, tax advisor or attorney, if and to the extent available, any information concerning a potential investment at the web sites of the U.S. Securities and Exchange Commission (the "SEC") at www.sec.gov; the Financial Industry Regulatory Authority (the "FINRA") at www.FINRA.org, and relevant State Securities Administrator website and the OTC Markets website at www.otcmarkets.com. The Publisher cautions investors to read the SEC advisory to investors concerning Internet Stock Fraud at www.sec.gov/consumer/cyberfr.htm, as well as related information published by the FINRA on how to invest carefully. Investors are responsible for verifying all information in the Advertisement. As an advertiser, we do not verify any information we publish. The Advertisement should not be considered true or complete.
The Publisher does not offer investment advice or analysis, and the Publisher further urges you to consult your own independent tax, business, financial and investment advisors concerning any investment you make in securities particularly those quoted on the OTC Markets. Investing in securities is highly speculative and carries an extremely high degree of risk. You could lose your entire investment if you invest in any company mentioned in the Advertisement. You acknowledge that we are not an investment advisory service, a broker-dealer or an investment adviser and we are not qualified to act as such. You acknowledge that you will consult with your own independent, tax, financial and/or legal advisers regarding any decisions as to any company mentioned here. We have not determined if the Advertisement is accurate, correct or truthful. The Advertisement is compiled from publicly available information, which include, but are not limited to, no cost online research, magazines, newspapers, reports filed with the SEC or information furnished by way of press releases. Because all information relied upon by us in preparing an advertisement about an issuer comes from a public source, it is not reliable, and you should not assume it is accurate or complete.
Owners and operators of the Publisher have been compensated nine thousand dollars by bank wire transfer on 4/9/26 for the distribution of this advertisement about SXTP from 60 Degrees Pharmaceuticals, Inc. dated 4/15/26. Prior to the past year, at the time of publication, we disclosed our compensation for the distribution of advertisements about SXTP. The Publisher and its owners and operators hold no stocks or bonds in companies discussed in the Advertisement. Owners and operators of the Publisher own several newsletters, therefore you may receive multiple publications and emails featuring companies at different or the same time.
You are receiving this report/release because you subscribed to receive it at our website or through a third-party site. All our newsletters include an "unsubscribe" link, and you can remove yourself at any time from our newsletters by clicking on that "unsubscribe" link. You can also contact us at [email protected] to change your information at any time. By your subscription to our profiles, the viewing of this profile and/or use of our website, you have agreed and acknowledged the terms of our full disclaimer and privacy policy which can be viewed at the following link:
www.SmallCapStocks.com/Disclaimer and www.SmallCapStocks.com/Privacy-Policy
By accepting the Advertisement, you agree and acknowledge that any hyperlinks to the website of (1) a client company, (2) the party issuing or preparing the information for the company, or (3) other information contained in the Advertisement is provided only for your reference and convenience. The advertiser is not responsible for the accuracy or reliability of these external sites, nor is it responsible for the content, opinions, products or other materials on external sites or information sources. If you use, act upon or make decisions in reliance on information contained in any disseminated report/release or any hyperlink, you do so at your own risk and agree to hold us, our officers, directors, shareholders, affiliates and agents harmless. You acknowledge that you are not relying on the Publisher, and we are not liable for, any actions taken by you based on any information contained in any disseminated email or hyperlink.